APO Research
Talk to an analyst

APO RESEARCH · REPORT

Maternal Pertussis Vaccine for Newborn Protection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Maternal Pertussis Vaccine for Newborn Protection Market Outlook and Growth Opportunities 2026

27 December 2025199 pages

Choose your research edition.

Industry ResearchMaternal Pertussis Vaccine for Newborn Protection Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Maternal Pertussis Vaccine for Newborn Protection Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Maternal Pertussis Vaccine for Newborn Protection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Maternal Pertussis Vaccine for Newborn Protection Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Maternal Pertussis Vaccine for Newborn Protection Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Maternal Pertussis Vaccine for Newborn Protection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Maternal Pertussis Vaccine for Newborn Protection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Maternal Pertussis Vaccine for Newborn Protection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Maternal Pertussis Vaccine for Newborn Protection market include Zhifei Biological, Walvax, Minhai Biological, GlaxoSmithKline, Sanofi Pasteur and Intravacc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Maternal Pertussis Vaccine for Newborn Protection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Maternal Pertussis Vaccine for Newborn Protection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Maternal Pertussis Vaccine for Newborn Protection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Maternal Pertussis Vaccine for Newborn Protection market size, projected growth trends, production technologies, key applications, and end-use industries.

Maternal Pertussis Vaccine for Newborn Protection Segment by Company

Zhifei Biological

Walvax

Minhai Biological

GlaxoSmithKline

Sanofi Pasteur

Intravacc

Maternal Pertussis Vaccine for Newborn Protection Segment by Type

Whole-cell Pertussis Vaccine

Acellular Pertussis Vaccine

Maternal Pertussis Vaccine for Newborn Protection Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Maternal Pertussis Vaccine for Newborn Protection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Maternal Pertussis Vaccine for Newborn Protection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Maternal Pertussis Vaccine for Newborn Protection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Maternal Pertussis Vaccine for Newborn Protection significant trends, drivers, influence factors in global and regions.

6. To analyze Maternal Pertussis Vaccine for Newborn Protection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Maternal Pertussis Vaccine for Newborn Protection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Maternal Pertussis Vaccine for Newborn Protection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Maternal Pertussis Vaccine for Newborn Protection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Maternal Pertussis Vaccine for Newborn Protection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Maternal Pertussis Vaccine for Newborn Protection industry.

Chapter 3: Detailed analysis of Maternal Pertussis Vaccine for Newborn Protection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Maternal Pertussis Vaccine for Newborn Protection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Maternal Pertussis Vaccine for Newborn Protection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Maternal Pertussis Vaccine for Newborn Protection Industry Trends Table 2. Maternal Pertussis Vaccine for Newborn Protection Industry Drivers Table 3. Maternal Pertussis Vaccine for Newborn Protection Industry Opportunities and Challenges Table 4. Maternal Pertussis Vaccine for Newborn Protection Industry Restraints Table 5. Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Maternal Pertussis Vaccine for Newborn Protection Revenue Share by Company (2021-2026) Table 7. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Company (Units) & (2021-2026) Table 8. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Company (2021-2026) Table 9. Global Maternal Pertussis Vaccine for Newborn Protection Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Maternal Pertussis Vaccine for Newborn Protection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Maternal Pertussis Vaccine for Newborn Protection Key Company Manufacturing Base & Headquarters Table 12. Global Maternal Pertussis Vaccine for Newborn Protection Company, Product Type & Application Table 13. Global Maternal Pertussis Vaccine for Newborn Protection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Maternal Pertussis Vaccine for Newborn Protection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Whole-cell Pertussis Vaccine Table 18. Significant Companies of Acellular Pertussis Vaccine Table 19. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 20. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2021-2026) & (Units) Table 21. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2027-2032) & (Units) Table 22. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Type (2021-2026) Table 23. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Type (2027-2032) Table 24. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type (2021-2026) Table 28. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Centers for Disease Control and Prevention Table 31. Significant Companies of Others Table 32. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 33. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2021-2026) & (Units) Table 34. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2027-2032) & (Units) Table 35. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Application (2021-2026) Table 36. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Application (2027-2032) Table 37. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application (2021-2026) Table 41. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application (2027-2032) Table 42. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 43. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2021-2026) & (Units) Table 44. Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Region (2021-2026) Table 45. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2027-2032) & (Units) Table 46. Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Region (2027-2032) Table 47. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Region (2021-2026) Table 50. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Region (2027-2032) Table 52. Global Maternal Pertussis Vaccine for Newborn Protection Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Maternal Pertussis Vaccine for Newborn Protection Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 55. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2026) & (Units) Table 57. Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Country (2021-2026) Table 58. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2027-2032) & (Units) Table 59. Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Country (2027-2032) Table 60. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Market Share by Country (2021-2026) Table 62. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Market Share by Country (2027-2032) Table 64. Zhifei Biological Company Information Table 65. Zhifei Biological Business Overview Table 66. Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio Table 68. Zhifei Biological Recent Development Table 69. Walvax Company Information Table 70. Walvax Business Overview Table 71. Walvax Maternal Pertussis Vaccine for Newborn Protection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Walvax Maternal Pertussis Vaccine for Newborn Protection Product Portfolio Table 73. Walvax Recent Development Table 74. Minhai Biological Company Information Table 75. Minhai Biological Business Overview Table 76. Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio Table 78. Minhai Biological Recent Development Table 79. GlaxoSmithKline Company Information Table 80. GlaxoSmithKline Business Overview Table 81. GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Product Portfolio Table 83. GlaxoSmithKline Recent Development Table 84. Sanofi Pasteur Company Information Table 85. Sanofi Pasteur Business Overview Table 86. Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Product Portfolio Table 88. Sanofi Pasteur Recent Development Table 89. Intravacc Company Information Table 90. Intravacc Business Overview Table 91. Intravacc Maternal Pertussis Vaccine for Newborn Protection Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Intravacc Maternal Pertussis Vaccine for Newborn Protection Product Portfolio Table 93. Intravacc Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Maternal Pertussis Vaccine for Newborn Protection Distributors List Table 97. Maternal Pertussis Vaccine for Newborn Protection Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Maternal Pertussis Vaccine for Newborn Protection Product Image Figure 2. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Maternal Pertussis Vaccine for Newborn Protection Sales (2021-2032) & (Units) Figure 5. Global Maternal Pertussis Vaccine for Newborn Protection Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Maternal Pertussis Vaccine for Newborn Protection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Whole-cell Pertussis Vaccine Image Figure 10. Acellular Pertussis Vaccine Image Figure 11. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 12. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Type (2021-2032) Figure 14. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Centers for Disease Control and Prevention Image Figure 19. Others Image Figure 20. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 21. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Application (2021-2032) Figure 23. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application (2021-2032) Figure 26. Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 27. Global Maternal Pertussis Vaccine for Newborn Protection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Maternal Pertussis Vaccine for Newborn Protection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Maternal Pertussis Vaccine for Newborn Protection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Whole-cell Pertussis Vaccine
  • Acellular Pertussis Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Zhifei Biological
  • Walvax
  • Minhai Biological
  • GlaxoSmithKline
  • Sanofi Pasteur
  • Intravacc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032)
  4. 1.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume (2021-2032)
  5. 1.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Maternal Pertussis Vaccine for Newborn Protection Market Dynamics
  1. 2.1 Maternal Pertussis Vaccine for Newborn Protection Industry Trends
  2. 2.2 Maternal Pertussis Vaccine for Newborn Protection Industry Drivers
  3. 2.3 Maternal Pertussis Vaccine for Newborn Protection Industry Opportunities and Challenges
  4. 2.4 Maternal Pertussis Vaccine for Newborn Protection Industry Restraints
3 Maternal Pertussis Vaccine for Newborn Protection Market by Company
  1. 3.1 Global Maternal Pertussis Vaccine for Newborn Protection Company Revenue Ranking in 2025
  2. 3.2 Global Maternal Pertussis Vaccine for Newborn Protection Revenue by Company (2021-2026)
  3. 3.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Company (2021-2026)
  4. 3.4 Global Maternal Pertussis Vaccine for Newborn Protection Average Price by Company (2021-2026)
  5. 3.5 Global Maternal Pertussis Vaccine for Newborn Protection Company Ranking (2024-2026)
  6. 3.6 Global Maternal Pertussis Vaccine for Newborn Protection Company Manufacturing Base and Headquarters
  7. 3.7 Global Maternal Pertussis Vaccine for Newborn Protection Company Product Type and Application
  8. 3.8 Global Maternal Pertussis Vaccine for Newborn Protection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Maternal Pertussis Vaccine for Newborn Protection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Maternal Pertussis Vaccine for Newborn Protection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Maternal Pertussis Vaccine for Newborn Protection Market by Type
  1. 4.1 Maternal Pertussis Vaccine for Newborn Protection Type Introduction
  2. 4.1.1 Whole-cell Pertussis Vaccine
  3. 4.1.2 Acellular Pertussis Vaccine
  4. 4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type
  5. 4.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type
  9. 4.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Type (2021-2032)
  11. 4.3.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type (2021-2032)
5 Maternal Pertussis Vaccine for Newborn Protection Market by Application
  1. 5.1 Maternal Pertussis Vaccine for Newborn Protection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application
  6. 5.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application
  10. 5.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Application (2021-2032)
  12. 5.3.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application (2021-2032)
6 Maternal Pertussis Vaccine for Newborn Protection Regional Sales and Value Analysis
  1. 6.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2021-2032)
  3. 6.2.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region: 2021-2026
  4. 6.2.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Region (2027-2032)
  5. 6.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Region (2027-2032)
  9. 6.5 Global Maternal Pertussis Vaccine for Newborn Protection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032)
  12. 6.6.2 North America Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032)
  15. 6.7.2 Europe Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032)
  21. 6.9.2 South America Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Country, 2025 VS 2032
7 Maternal Pertussis Vaccine for Newborn Protection Country-level Sales and Value Analysis
  1. 7.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2032)
  4. 7.3.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2021-2026)
  5. 7.3.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales by Country (2027-2032)
  6. 7.4 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Maternal Pertussis Vaccine for Newborn Protection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Maternal Pertussis Vaccine for Newborn Protection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhifei Biological
  2. 8.1.1 Zhifei Biological Company Information
  3. 8.1.2 Zhifei Biological Business Overview
  4. 8.1.3 Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Zhifei Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
  6. 8.1.5 Zhifei Biological Recent Developments
  7. 8.2 Walvax
  8. 8.2.1 Walvax Company Information
  9. 8.2.2 Walvax Business Overview
  10. 8.2.3 Walvax Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Walvax Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
  12. 8.2.5 Walvax Recent Developments
  13. 8.3 Minhai Biological
  14. 8.3.1 Minhai Biological Company Information
  15. 8.3.2 Minhai Biological Business Overview
  16. 8.3.3 Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Minhai Biological Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
  18. 8.3.5 Minhai Biological Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Sanofi Pasteur
  26. 8.5.1 Sanofi Pasteur Company Information
  27. 8.5.2 Sanofi Pasteur Business Overview
  28. 8.5.3 Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Pasteur Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
  30. 8.5.5 Sanofi Pasteur Recent Developments
  31. 8.6 Intravacc
  32. 8.6.1 Intravacc Company Information
  33. 8.6.2 Intravacc Business Overview
  34. 8.6.3 Intravacc Maternal Pertussis Vaccine for Newborn Protection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Intravacc Maternal Pertussis Vaccine for Newborn Protection Product Portfolio
  36. 8.6.5 Intravacc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Maternal Pertussis Vaccine for Newborn Protection Value Chain Analysis
  2. 9.1.1 Maternal Pertussis Vaccine for Newborn Protection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Maternal Pertussis Vaccine for Newborn Protection Sales Mode & Process
  6. 9.2 Maternal Pertussis Vaccine for Newborn Protection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Maternal Pertussis Vaccine for Newborn Protection Distributors
  9. 9.2.3 Maternal Pertussis Vaccine for Newborn Protection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst